Player Avatar flynthewest (< 20) Submitted: 11/16/2012 11:40:26 AM : Outperform Start Price: $40.04 SNY Score: -13.28

Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that SNY's history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.

Featured Broker Partners